Suppr超能文献

羟氯喹治疗门诊轻度症状 COVID-19 患者:一项多中心观察性研究。

Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.

机构信息

Division of Outcomes and Value Research, John Theurer Cancer Center at Hackensack University Medical Center, 92 Second Street, Hackensack, NJ, 07601, USA.

Hackensack Meridian Health, Hackensack, NJ, USA.

出版信息

BMC Infect Dis. 2021 Jan 14;21(1):72. doi: 10.1186/s12879-021-05773-w.

Abstract

BACKGROUND

Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.

METHODS

We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching.

RESULTS

Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available.

CONCLUSIONS

In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.

摘要

背景

在大多数观察性研究中,羟氯喹并未与住院 COVID-19 患者的生存率提高相关,同样,在一项前瞻性随机试验中,羟氯喹也未被确定为有效的预防药物。我们旨在探讨羟氯喹治疗在门诊轻度症状 COVID-19 患者中的作用。

方法

我们研究了门诊羟氯喹暴露与已确诊 SARS-CoV-2 感染的轻度症状非住院患者疾病进展之间的关系。主要评估指标是住院需求。数据来自美国新泽西州一个多医院网络的电子病历回顾。我们通过多变量逻辑模型和倾向匹配比较了接受羟氯喹和未接受羟氯喹的患者的结局。

结果

在 1274 例有记录的 SARS-CoV-2 感染门诊患者中,7.6%接受了羟氯喹治疗。在 1067 例有倾向匹配的患者队列中,有门诊羟氯喹暴露的患者中 21.6%住院,无暴露的患者中 31.4%住院。在倾向匹配的主要多变量逻辑回归分析中,羟氯喹暴露与 COVID-19 住院率降低相关(OR 0.53;95%CI,0.29,0.95)。敏感性分析显示出相似的关联。接受羟氯喹治疗的患者中有 2%出现 QTc 延长事件,但无报告心律失常事件。

结论

在这项对非住院 SARS-CoV-2 感染患者的回顾性观察性研究中,羟氯喹暴露与随后住院率降低相关。在这一轻度症状的门诊人群中,进一步探索羟氯喹的作用是必要的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cca/7807443/d2ba44112b00/12879_2021_5773_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验